PP01.25 Incidence and Timing of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor as Monotherapy or in Combination With Chemotherapy

Immune-checkpoint inhibitors (ICI) combined with chemotherapy is an FDA approved and standard approach for treating non-small cell lung cancer (NSCLC). Immune-related adverse events (irAEs) are a unique set of toxicities that occur with ICI and have been shown to be correlated with increased overall survival (OS). Most studies conducted to date have focused only on ICI without chemotherapy. In this study, 217 NSCLC patients treated first-line with either ICI alone or in combination with chemotherapy (ICI-Chemo) were evaluated to investigate differences in incidence, risk factors, effect on OS, or timing of irAEs between treatment groups.